Registered outcomes14

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 14 of 14

List	Outcome	Time frame	Description
Primary	Effectiveness of regorafenib use in routine clinical practice setting, assessed by overall survival (OS)	through study completion, estimated 2 years	months
Primary	Effectiveness of regorafenib use in routine clinical practice setting, assessed by progression free survival (PFS)	through study completion, estimated 2 years	months
Primary	Effectiveness of regorafenib use in routine clinical practice setting, assessed by time to progression (TTP)	through study completion, estimated 2 years	months
Primary	Effectiveness of regorafenib use in routine clinical practice setting, assessed by tumor response	through study completion, estimated 2 years	percentage
Secondary	Safety of regorafenib use in routine clinical practice setting, assessed by incidence of adverse events (AEs)	through study completion, estimated 2 years	percentage
Secondary	Safety of regorafenib use in routine clinical practice setting, assessed by initial dose	through study completion, estimated 2 years	percentage
Secondary	Safety of regorafenib use in routine clinical practice setting, assessed by dose intensity during the first 2 cycles	through study completion, estimated 2 years	percentage
Secondary	Eligibility of subsequent therapies and the outcome, assessed by type of treatment (anti-epithelial growth factor receptor [EGFR], anti-vascular endothelial growth factor [VEGF], and/or chemotherapy agents)	through study completion, estimated 2 years	percentage
Secondary	Eligibility of subsequent therapies and the outcome, assessed by treatment duration	through study completion, estimated 2 years	months
Secondary	Eligibility of subsequent therapies and the outcome, assessed by PFS	through study completion, estimated 2 years	months
Other	Exploratory outcome:Clinical markers/ biomarkers as the potential predictive factor for regorafenib treatment outcome in overall cohort and long-term responders, assessed by patient characteristics	through study completion, estimated 2 years	correlation
Other	Exploratory outcome:Clinical markers/ biomarkers as the potential predictive factor for regorafenib treatment outcome in overall cohort and long-term responders, assessed by changes in carcinoembryonic antigen (CEA) levels	through study completion, estimated 2 years	correlation
Other	Exploratory outcome:Clinical markers/ biomarkers as the potential predictive factor for regorafenib treatment outcome in overall cohort and long-term responders, assessed by changes in carbohydrate antigen (CA19-9) levels	through study completion, estimated 2 years	correlation
Other	Exploratory outcome: Image pattern as the potential predictive factor for regorafenib treatment outcome in overall cohort and long-term responders, assessed by changes in image patterns	through study completion, estimated 2 years	correlation

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03829852/registered

API reference For AI assistants